Literature DB >> 16513171

Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo.

Judith M H de Jong1, Danita H Schuurhuis, Andreea Ioan-Facsinay, Ellen I H van der Voort, Tom W J Huizinga, Ferry Ossendorp, René E M Toes, J Sjef Verbeek.   

Abstract

Antigen(Ag)-immunoglobulin (Ig)G complexes (IC) are more efficiently processed and presented than soluble Ag. IC can bind to various cell types via different types of Fc-Receptors or, upon binding to complement factors, by complement receptors. Murine professional antigen-presenting cells (APC) express four types of FcgammaReceptors (FcgammaR) via which they are able to capture IC; three activating receptors (FcgammaRI, III and IV) and one inhibitory receptor (FcgammaRII). It has been demonstrated that FcgammaR play a pivotal role in facilitating the presentation of Ag derived from IC. Nonetheless, relative little information is available on the relative contribution of the activating or inhibitory FcgammaR or complement to the presentation of immune-complexed Ag to CD8+ T cells. To study the contribution of the different FcgammaR and complement receptors in IC-facilitated Ag-presentation, we analyzed the ovalbumin(OVA)-specific CD8+ T cell proliferation in FcgammaR- and complement component 3 (C3)-deficient mice after subcutaneous injection of OVA-IC. Here we show that the efficient Ag-presentation was FcgammaR-, but not C3-mediated, as it was inhibited in FcgammaRI/II/III-deficient mice but unaffected in the C3-depleted mice. Moreover, FcgammaRIV does not play a role under these conditions. However, no difference was found between wild-type and FcgammaRI/III-deficient or wild-type and FcgammaRII-deficient mice. These results indicate that Ag-presentation via the activating FcgammaR is not enhanced in the absence of FcgammaRII, and point to redundancy of the FcgammaR, including FcgammaRII, in the uptake and presentation of s.c. injected soluble IC to CD8+ T cells.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16513171     DOI: 10.1016/j.molimm.2006.01.002

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  18 in total

1.  A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.

Authors:  Waranyoo Phoolcharoen; John M Dye; Jacquelyn Kilbourne; Khanrat Piensook; William D Pratt; Charles J Arntzen; Qiang Chen; Hugh S Mason; Melissa M Herbst-Kralovetz
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana.

Authors:  Waranyoo Phoolcharoen; Seong H Bhoo; Huafang Lai; Julian Ma; Charles J Arntzen; Qiang Chen; Hugh S Mason
Journal:  Plant Biotechnol J       Date:  2011-02-01       Impact factor: 9.803

3.  Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity.

Authors:  Yaron Carmi; Tyler R Prestwood; Matthew H Spitzer; Ian L Linde; Jonathan Chabon; Nathan E Reticker-Flynn; Nupur Bhattacharya; Hong Zhang; Xiangyue Zhang; Pamela A Basto; Bryan M Burt; Michael N Alonso; Edgar G Engleman
Journal:  JCI Insight       Date:  2016-11-03

Review 4.  The function of Fcγ receptors in dendritic cells and macrophages.

Authors:  Martin Guilliams; Pierre Bruhns; Yvan Saeys; Hamida Hammad; Bart N Lambrecht
Journal:  Nat Rev Immunol       Date:  2014-01-21       Impact factor: 53.106

5.  Divergent intracellular sorting of Fc{gamma}RIIA and Fc{gamma}RIIB2.

Authors:  Christine Y Zhang; James W Booth
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

6.  How to connect an IgE-driven response with CTL activity?

Authors:  Barbara Platzer; Eleonora Dehlink; Shannon J Turley; Edda Fiebiger
Journal:  Cancer Immunol Immunother       Date:  2011-11-01       Impact factor: 6.968

7.  Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen.

Authors:  Andrew G Diamos; Dalia Larios; Lauren Brown; Jacquelyn Kilbourne; Hyun Soon Kim; Divyasha Saxena; Kenneth E Palmer; Hugh S Mason
Journal:  Vaccine       Date:  2018-11-17       Impact factor: 3.641

Review 8.  Cross-presentation of IgG-containing immune complexes.

Authors:  Kristi Baker; Timo Rath; Wayne I Lencer; Edda Fiebiger; Richard S Blumberg
Journal:  Cell Mol Life Sci       Date:  2012-07-31       Impact factor: 9.261

Review 9.  Targeting antigens to dendritic cell receptors for vaccine development.

Authors:  Vasso Apostolopoulos; Theresia Thalhammer; Andreas G Tzakos; Lily Stojanovska
Journal:  J Drug Deliv       Date:  2013-10-08

10.  Engineered hepatitis B virus surface antigen L protein particles for in vivo active targeting of splenic dendritic cells.

Authors:  Hidenori Matsuo; Nobuo Yoshimoto; Masumi Iijima; Tomoaki Niimi; Joohee Jung; Seong-Yun Jeong; Eun Kyung Choi; Tomomitsu Sewaki; Takeshi Arakawa; Shun'ichi Kuroda
Journal:  Int J Nanomedicine       Date:  2012-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.